leisure time -WSS

leisure time

author：Wikipedia 2025-09-27 07:51:15 - browse：749

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： 6 solutions to address cancer drug shortages and others

leisure time

WSS

Liquid biopsy for lung cancer is launched by Delfi

Stroke deaths set to near 10 million globally by 2050

CDC picks Alphabet's Verily for wasterwater surveillance contract

The biotech scorecard for Q4: 16 stock

Study points to new risk in gene therapy death of Terry Horgan

Physician executives need more than on

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The stability of $0 premiums in Medicare Advantage

Medicare proposal to cover medical devices draws a mixed reaction

Was Amgen transparent enough on FDA's concern on cancer drug?

Supreme Court strikes down use of affirmative action

With Roe v Wade overturned, abortion providers work to adapt

Novavax promises a turnaround & Lilly roils the obesity market

Lawsuit highlights wrinkle for disputes over surprise medical bills

Hollywood unions extend contract negotiations for actors

Physician executives need more than on

entertainment

FDA panel signals lack of confidence in Amgen cancer drug data

Health insurers' Q3 question: how much care are people getting?

AI can decode, harness the power of the humane immune system

Stop Congress from blocking public access to science

CRISPR base editing slashes cholesterol levels in monkeys

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

explore

entertainment

leisure time

hotspot